Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Midodrine · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Midodrine HCl Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | ProAmatine® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Midodrine HCl Tablets 5 mg | DRUG | 5mg, single dose fed |
| ProAmatine® Tablets 5 mg | DRUG | 5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...
Midodrine is a small molecule drug developed by Viatris Inc. (ticker: VTRS). It is also known as Midodrine HCl Tablets 5 mg. The drug has been studied in Phase 1 clinical trials, with three completed trials involving a total of 97 healthy volunteers. The specific therapeutic indication for Midodrine is currently undisclosed.
Midodrine targets the alpha-1 adrenergic receptors ADRA1A, ADRA1D, and ADRA1B. It acts as an agonist at these receptors. By activating these targets, Midodrine exerts its pharmacological effects. The molecular target information is based on ChEMBL ID CHEMBL1201212.
Midodrine is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the development of Midodrine HCl Tablets 5 mg.
Midodrine is in Phase 1 of clinical development. All three of its clinical trials are completed, and there are currently no active trials. The drug has been tested in a total of 97 participants across these Phase 1 studies.
Midodrine has been studied in three completed Phase 1 clinical trials: NCT00650364 (fasting study, 38 participants), NCT00650013 (fed study, 23 participants), and NCT00648440 (food study, 36 participants). All trials were conducted in the United States with healthy volunteers and were active-controlled.